Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

#AANAM – CLES Led to Sustained Reductions in ‘Off’ Time

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Carbidopa/levodopa enteral suspension (CLES) provided long-term, sustained, and clinically meaningful reductions in “off” time for people with Parkinson’s disease, according…

Virtual Phase 3 Trial of At-home Light Therapy May Open in Summer 

PhotoPharmics plans to open, possibly this summer, a pivotal Phase 3 clinical trial of its light-based and noninvasive Celeste device in treating Parkinson’s symptoms, for use by patients at home and with trial goals evaluated using telemedicine. A particular company goal for this device, PhotoPharmics also announced, is reaching underserved patients…

Antibody-based Therapies May Trigger Brain Inflammation

New research suggests that brain inflammation is the likely reason antibody-based therapies are ineffective in clinical trials for people with Parkinson’s and Alzheimer’s diseases. The findings show that the binding of the antibody to its target protein — in the case of Parkinson’s disease the misfolded alpha-synuclein —…

Fox Foundation Grant to Help Advance CNM-Au8 to Planned Phase 2 Trial

A grant from the Michael J. Fox Foundation (MJFF) will help Clene Nanomedicine to advance in development CNM-Au8, its cellular energy-promoting, investigational Parkinson’s treatment. The grant will help to support preclinical studies in patients’ nerve cells and mouse models of the disease, as well as facilitate the launch of a Phase 2 safety and effectiveness…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums